Endo International, the Dublin-based pharmaceutical company that has its U.S. headquarters in Malvern, is searching for a new CEO, writes John George for the Philadelphia Business Journal.

Last week, Paul Campanelli, who has served as the company’s CEO since 2016, announced his intent to retire. However, he will not be leaving his position as president and CEO until his successor is named.

Meanwhile, effective immediately, Campanelli has been appointed chairman of the board and will continue in this role after the new CEO is found. Roger Kimmel, Endo’s previous chairman of the board, has been appointed senior independent director.

“I am proud of what the Endo team has accomplished, and I am confident we have positioned the company for long-term growth and success,” said Campanelli.

For the first nine months of this year, Endo has generated almost $2.15 billion in revenue, cutting its operational loss to $152 million. This is a significant decrease from the $696 million from the same period last year.

Read more about Endo in the Philadelphia Business Journal here.

[uam_ad id=”80503″]

.

[uam_ad id=”80502″]